ATE359286T1 - Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika - Google Patents

Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika

Info

Publication number
ATE359286T1
ATE359286T1 AT02778894T AT02778894T ATE359286T1 AT E359286 T1 ATE359286 T1 AT E359286T1 AT 02778894 T AT02778894 T AT 02778894T AT 02778894 T AT02778894 T AT 02778894T AT E359286 T1 ATE359286 T1 AT E359286T1
Authority
AT
Austria
Prior art keywords
antibiotics
production
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
AT02778894T
Other languages
English (en)
Inventor
Joseph Aszodi
Maxime Lampilas
Branislav Musicki
David Alan Rowlands
Pascal Collette
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novexel filed Critical Novexel
Application granted granted Critical
Publication of ATE359286T1 publication Critical patent/ATE359286T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02778894T 2001-06-08 2002-06-04 Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika ATE359286T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0107520A FR2825705B1 (fr) 2001-06-08 2001-06-08 Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Publications (1)

Publication Number Publication Date
ATE359286T1 true ATE359286T1 (de) 2007-05-15

Family

ID=8864102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02778894T ATE359286T1 (de) 2001-06-08 2002-06-04 Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika

Country Status (15)

Country Link
US (2) US7288549B2 (de)
EP (2) EP1399444B1 (de)
JP (1) JP4509551B2 (de)
AR (1) AR036091A1 (de)
AT (1) ATE359286T1 (de)
CA (1) CA2449830C (de)
CY (1) CY1106801T1 (de)
DE (1) DE60219469T2 (de)
DK (1) DK1399444T3 (de)
ES (1) ES2284938T3 (de)
FR (1) FR2825705B1 (de)
IL (1) IL158756A0 (de)
MX (1) MXPA03011039A (de)
PT (1) PT1399444E (de)
WO (1) WO2002100860A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) * 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
DE102004004974A1 (de) * 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
EP2077262A4 (de) * 2006-10-23 2011-12-28 Takeda Pharmaceutical Iminopyridinderivate und deren verwendung
FR2914923B1 (fr) * 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
FR2916444B1 (fr) * 2007-05-25 2011-02-11 Sanofi Aventis Procede de preparation de n-carboxyanhydride enantiomeriquement enrichi.
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
CL2009000964A1 (es) * 2008-04-23 2010-03-26 Takeda Pharmaceuticals Co Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
US8853237B2 (en) 2010-12-30 2014-10-07 Vanderbilt University Naphthyridinone analogs as mGluR5 positive allosteric modulators
US8710074B2 (en) * 2011-01-12 2014-04-29 Vanderbilt University Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mGluR5 modulators
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
JP5881514B2 (ja) * 2012-04-09 2016-03-09 株式会社トクヤマ アミン誘導体の製造方法
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CN103910676B (zh) * 2013-01-04 2015-11-18 华东师范大学 一种多取代四氢异喹啉衍生物的合成方法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
JP6453222B2 (ja) 2013-09-24 2019-01-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
ES2901198T3 (es) 2013-10-08 2022-03-21 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas
JP6764862B2 (ja) * 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
MY190283A (en) 2014-12-05 2022-04-12 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
EP3075381A1 (de) * 2015-04-03 2016-10-05 Mutabilis Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
WO2016156597A1 (en) * 2015-04-03 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3184529A1 (de) 2015-12-23 2017-06-28 Mutabilis Heterocyclische verbindungen und deren verwendung zur vorbeugung oder behandlung von bakteriellen infektionen
DK3512851T3 (en) * 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3300736B1 (de) * 2016-09-30 2021-05-05 Mutabilis Zusammensetzung mit einer antibiotischen verbindung und heterocyclischen verbindung und deren verwendung bei der vorbeugung oder behandlung bakterieller infektionen
CN108239089B (zh) * 2016-12-27 2020-05-22 浙江医药股份有限公司新昌制药厂 一种阿维巴坦钠的合成方法
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
EP3357924A1 (de) * 2017-02-06 2018-08-08 Mutabilis Neuartige heterocyclische verbindungen und deren verwendung bei der vorbeugung oder behandlung von bakteriellen infektionen
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
WO2018208769A1 (en) 2017-05-08 2018-11-15 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109678855B (zh) 2017-10-18 2020-07-17 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN108276408B (zh) * 2018-04-19 2020-09-29 上海皓元医药股份有限公司 一种曲贝替定的中间体及其制备方法和用途
EP3604309A1 (de) 2018-07-30 2020-02-05 Mutabilis Heterocyclische verbindungen und deren verwendung in der vorbeugung oder behandlung von bakteriellen infektionen
EP3604315A1 (de) * 2018-07-30 2020-02-05 Mutabilis Heterocyclische verbindungen und deren verwendung in der vorbeugung oder behandlung von bakteriellen infektionen
CN115151544B (zh) 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
CN111978321A (zh) * 2020-09-22 2020-11-24 海南梵圣生物科技有限公司 一种4-Boc-2,5,6,7-四氢吡唑并[4,3-b]吡啶及其衍生物的制备方法
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
WO2024227071A1 (en) * 2023-04-26 2024-10-31 Entasis Therapeutics Limited Synthesis of durlobactam

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654282A (en) * 1969-08-21 1972-04-04 Houde Lab 1 2 3 4-tetrahydro-isoquinoline 1-carboxylic acids
US3629265A (en) * 1969-10-30 1971-12-21 Hoffmann La Roche 7-halo-4-isoquinolones
CA2051697C (en) * 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
JPH05339263A (ja) * 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
PT1227103E (pt) * 1993-09-29 2006-12-29 Univ Maryland Nucleótidos de anel expandido
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) * 1995-12-22 1995-12-22 Astra Ab New Compounds
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
EP1070054A1 (de) * 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Aminverbindungen, ihre herstellung und ihre verwendung als somatostatin rezeptor antagonisten oder agonisten
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
TR200101754T2 (tr) * 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
EP1227090A4 (de) * 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd Aminderivate
EP1288216A1 (de) * 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclische chinazolindione
CN100334213C (zh) * 2000-12-22 2007-08-29 巴斯福股份公司 棒状杆菌基因
US7179921B2 (en) * 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Also Published As

Publication number Publication date
DK1399444T3 (da) 2007-06-04
ES2284938T3 (es) 2007-11-16
FR2825705B1 (fr) 2005-05-20
JP4509551B2 (ja) 2010-07-21
EP1399444A2 (de) 2004-03-24
US7288549B2 (en) 2007-10-30
CA2449830C (en) 2012-11-27
DE60219469D1 (de) 2007-05-24
FR2825705A1 (fr) 2002-12-13
IL158756A0 (en) 2004-05-12
JP2005518333A (ja) 2005-06-23
AR036091A1 (es) 2004-08-11
EP1798231A3 (de) 2008-02-27
US20070299108A1 (en) 2007-12-27
WO2002100860A2 (fr) 2002-12-19
DE60219469T2 (de) 2007-11-29
PT1399444E (pt) 2007-05-31
MXPA03011039A (es) 2004-03-19
CA2449830A1 (en) 2002-12-19
EP1399444B1 (de) 2007-04-11
EP1798231A2 (de) 2007-06-20
WO2002100860A3 (fr) 2003-11-20
US20050245505A1 (en) 2005-11-03
US8148540B2 (en) 2012-04-03
CY1106801T1 (el) 2012-05-23

Similar Documents

Publication Publication Date Title
ATE359286T1 (de) Heterozyklische verbindungen, verfahren zu deren herstellung sowie deren verwendung als antibiotika
ATE476412T1 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
DE60208373D1 (de) Polyaryleneether-polyolefinzusammensetzung, verfahren zu deren herstellung und formassen daraus
DE50113328D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE60022866D1 (de) Bizyklische heterozyklen, diese verbindungen enthaltende zusammenstellungen und verfahren zu deren herstellung
ATE332898T1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE502004008951D1 (de) Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE50111799D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE394392T1 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE50111293D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50110906D1 (de) Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50300813D1 (de) Neue fluorencarbonsaureester, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE50114874D1 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1228061A4 (de) Dipeptidyl-peptidase-iv-inhibitoren, verfahren zu deren herstellung sowie deren verwendung
DE502005010912D1 (de) Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60333438D1 (de) Beschichtete gefässprothesen, verfahren zu deren herstellung und verwendung derselben
ATE347890T1 (de) Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren
DE50310783D1 (de) Neue thiophenglycosidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE60205555D1 (de) Fluorinierte cycloolefinpolymere und verfahren zu deren herstellung, sowie deren verwendung
ATE346065T1 (de) Substituierte thiazol- benzoisothiazoldioxidderivative, verfahren zu deren herstellung und deren verwendung
ATE348609T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
ATE482193T1 (de) Indolonacetamidderivate, verfahren zu deren herstellung und deren verwendungen
ATE327981T1 (de) Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
ATE496046T1 (de) Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
DE502004005578D1 (de) Hochtackige klebmasse, verfahren zu deren herstellung und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399444

Country of ref document: EP